Investigation of polymeric amphiphilic nanoparticles as antitumor drug carriers
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhang, Jing | - |
dc.contributor.author | Chen, Xi Guang | - |
dc.contributor.author | Liu, Cheng Sheng | - |
dc.contributor.author | Park, Hyun Jin | - |
dc.date.accessioned | 2021-09-08T18:45:17Z | - |
dc.date.available | 2021-09-08T18:45:17Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2009-04 | - |
dc.identifier.issn | 0957-4530 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/120389 | - |
dc.description.abstract | In this paper, polymeric amphiphilic nanoparticles based on oleoyl-chitosan (OCH) with different degrees of substitution (DS, 5%, 11% and 27%) were prepared by Oil/Water emulsification method. Mean diameters of the nanoparticles were 327.4 nm, 255.3 nm and 192.6 nm, respectively. Doxorubicin (DOX) was efficiently loaded into OCH nanoparticles and provided a sustained released after a burst release in PBS. These nanoparticles showed no cytotoxicity to mouse embryo fibroblasts (MEF) and low hemolysis rates (< 5%). The results of SDS-PAGE indicated that bovine calf serum (BCS) adsorption on OCH nanoparticles was inhibited by smaller particle size. Cellular uptake was evaluated by incubating fluorescence labeled OCH nanoparticles with human lung carcinoma cells (A549) and mouse macrophages (RAW264.7). Cellular uptake of OCH nanoparticles was time--and concentration--dependent. Finding the appropriate incubation time and concentration of OCH nanoparticles used as drug carriers might decrease phagocytic uptake, increase cancer cell uptake and ultimately improve therapeutic efficiency of antitumor therapeutic agents. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | PEG CHAIN-LENGTH | - |
dc.subject | CHITOSAN NANOPARTICLES | - |
dc.subject | DELIVERY | - |
dc.subject | BIODISTRIBUTION | - |
dc.subject | RELEASE | - |
dc.subject | CANCER | - |
dc.subject | COPOLYMER | - |
dc.subject | MICELLES | - |
dc.subject | EFFICACY | - |
dc.subject | THERAPY | - |
dc.title | Investigation of polymeric amphiphilic nanoparticles as antitumor drug carriers | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Hyun Jin | - |
dc.identifier.doi | 10.1007/s10856-008-3656-2 | - |
dc.identifier.scopusid | 2-s2.0-61349114216 | - |
dc.identifier.wosid | 000263683900019 | - |
dc.identifier.bibliographicCitation | JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE, v.20, no.4, pp.991 - 999 | - |
dc.relation.isPartOf | JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE | - |
dc.citation.title | JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE | - |
dc.citation.volume | 20 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 991 | - |
dc.citation.endPage | 999 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Engineering | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Engineering, Biomedical | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Biomaterials | - |
dc.subject.keywordPlus | PEG CHAIN-LENGTH | - |
dc.subject.keywordPlus | CHITOSAN NANOPARTICLES | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | BIODISTRIBUTION | - |
dc.subject.keywordPlus | RELEASE | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | COPOLYMER | - |
dc.subject.keywordPlus | MICELLES | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | THERAPY | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.